Goldman Sachs
ABEO icon

Goldman Sachs’s Abeona Therapeutics ABEO Stock Holding History

Goldman Sachs’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.07M Buy
1,130,619
+628,435
+125% +$3.14M ﹤0.01% 3679
2025
Q4 		$2.65M Buy
502,184
+179,753
+56% +$905K ﹤0.01% 4325
2025
Q3 		$1.7M Buy
322,431
+185,285
+135% +$1.18M ﹤0.01% 4615
2025
Q2 		$779K Sell
137,146
-63,304
-32% -$360K ﹤0.01% 4872
2025
Q1 		$954K Buy
200,450
+66,422
+50% +$361K ﹤0.01% 4711
2024
Q4 		$747K Buy
+134,028
New +$825K ﹤0.01% 5021
2024
Q2 		– Sell
-171,533
Closed -$1.24M – 5624
2024
Q1 		$1.24M Buy
+171,533
New +$1.09M ﹤0.01% 4201
2023
Q3 		– Sell
-213,282
Closed -$860K – 5511
2023
Q2 		$860K Buy
213,282
+50,008
+31% +$175K ﹤0.01% 4450
2023
Q1 		$460K Sell
163,274
-6,387
-4% -$16.7K ﹤0.01% 4863
2022
Q4 		$523K Buy
+169,661
New +$635K ﹤0.01% 4842
2021
Q4 		– Sell
-4,528
Closed -$127K – 6435
2021
Q3 		$127K Sell
4,528
-8,654
-66% -$277K ﹤0.01% 5865
2021
Q2 		$515K Buy
13,182
+7,808
+145% +$319K ﹤0.01% 5195
2021
Q1 		$252K Buy
5,374
+3,412
+174% +$188K ﹤0.01% 5514
2020
Q4 		$77K Sell
1,962
-7,413
-79% -$253K ﹤0.01% 5329
2020
Q3 		$239K Buy
9,375
+423
+5% +$26.7K ﹤0.01% 4845
2020
Q2 		$652K Sell
8,952
-3,416
-28% -$236K ﹤0.01% 4228
2020
Q1 		$649K Buy
12,368
+1,225
+11% +$81.8K ﹤0.01% 4049
2019
Q4 		$911K Buy
11,143
+1,296
+13% +$91.4K ﹤0.01% 4186
2019
Q3 		$556K Buy
9,847
+6,756
+219% +$506K ﹤0.01% 4393
2019
Q2 		$369K Buy
3,091
+963
+45% +$161K ﹤0.01% 4516
2019
Q1 		$392K Buy
2,128
+428
+25% +$76.5K ﹤0.01% 4521
2018
Q4 		$304K Sell
1,700
-462
-21% -$101K ﹤0.01% 4628
2018
Q3 		$692K Buy
2,162
+1,512
+233% +$536K ﹤0.01% 4243
2018
Q2 		$260K Sell
650
-1,620
-71% -$708K ﹤0.01% 4857
2018
Q1 		$815K Sell
2,270
-1,198
-35% -$445K ﹤0.01% 4176
2017
Q4 		$1.37M Sell
3,468
-2,277
-40% -$942K ﹤0.01% 4091
2017
Q3 		$2.45M Buy
5,745
+5,321
+1,255% +$1.43M ﹤0.01% 3799
2017
Q2 		$68K Sell
424
-4,216
-91% -$575K ﹤0.01% 6274
2017
Q1 		$580K Buy
4,640
+4,162
+871% +$537K ﹤0.01% 4871
2016
Q4 		$58K Sell
478
-2,260
-83% -$354K ﹤0.01% 6345
2016
Q3 		$411K Buy
2,738
+2,036
+290% +$199K ﹤0.01% 5214
2016
Q2 		$41K Buy
702
+217
+45% +$14.8K ﹤0.01% 6483
2016
Q1 		$31K Sell
485
-404
-45% -$26.8K ﹤0.01% 6606
2015
Q4 		$75K Buy
+889
New +$89.2K ﹤0.01% 6323

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's ABEO Position: Q1 2026 in Review

Goldman Sachs increased its Abeona Therapeutics (ABEO) stake by 125% in Q1 2026, buying an estimated $3.14M and bringing the position to 1,130,619 shares worth $5.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3679.

Goldman Sachs first reported a position in ABEO in Q4 2015 and has held it in 34 quarters since. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Goldman Sachs held 1,130,619 shares of Abeona Therapeutics worth $5.07M as of Q1 2026.
  • Goldman Sachs bought 628,435 Abeona Therapeutics shares in Q1 2026, an estimated $3.14M.
  • Abeona Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3679 holding.
  • Goldman Sachs first reported a position in Abeona Therapeutics in Q4 2015 and has held it in 34 quarters since.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.